Natixis Advisors LLC Acquires 117,162 Shares of AstraZeneca PLC (NASDAQ:AZN)

Natixis Advisors LLC grew its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 6.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,960,815 shares of the company's stock after buying an additional 117,162 shares during the quarter. Natixis Advisors LLC owned approximately 0.06% of AstraZeneca worth $152,767,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. McClarren Financial Advisors Inc. raised its stake in shares of AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock valued at $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. bought a new position in AstraZeneca during the second quarter worth about $26,000. Capital Performance Advisors LLP bought a new stake in shares of AstraZeneca in the 3rd quarter valued at approximately $28,000. Pathway Financial Advisers LLC bought a new stake in AstraZeneca in the first quarter valued at $29,000. Finally, CANADA LIFE ASSURANCE Co grew its holdings in shares of AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company's stock worth $34,000 after purchasing an additional 146 shares during the last quarter. Institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Down 2.8 %

Shares of NASDAQ AZN traded down $1.81 during mid-day trading on Friday, reaching $63.23. 7,374,578 shares of the company's stock were exchanged, compared to its average volume of 7,079,173. The company has a current ratio of 0.93, a quick ratio of 0.69 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $75.03 and a 200 day simple moving average of $78.20. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The firm has a market capitalization of $196.05 billion, a price-to-earnings ratio of 30.25, a PEG ratio of 1.20 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the company posted $0.87 EPS. The business's quarterly revenue was up 18.0% on a year-over-year basis. As a group, equities analysts expect that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

Analyst Ratings Changes

AZN has been the topic of a number of research analyst reports. TD Cowen increased their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. Finally, Erste Group Bank upgraded AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.